Patents
Literature
10 results about "Antigen processing" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
'Antigen processing or cytosolic' pathway is an immunological process that prepares antigens for presentation to special cells of the immune system called T lymphocytes. It is considered to be a stage of antigen presentation pathways. This process involves two distinct pathways for processing of antigens from an organism's own (self) proteins or intracellular pathogens (e.g. viruses), or from phagocytosed pathogens (e.g. bacteria); subsequent presentation of these antigens on class I or class II major histocompatibility complex (MHC) molecules is dependent on which pathway is used. Both MHC class I and II are required to bind antigen before they are stably expressed on a cell surface. MHC I antigen presentation typically (considering cross-presentation) involves the endogenous pathway of antigen processing, and MHC II antigen presentation involves the exogenous pathway of antigen processing. Cross-presentation involves parts of the exogenous and the endogenous pathways but ultimately involves the latter portion of the endogenous pathway (e.g. proteolysis of antigens for binding to MHC I molecules).
Tolerogenic peptides
PendingUS20260034200A1Metabolism disorderPeptide/protein ingredientsAntigen processingPancreatic A Cells
The present disclosure is based in part on studies on novel tolerogenic peptides derived from a protein expressed by a pancreatic cell, which have been developed for use in antigen-specific immunotherapy for type 1 diabetes. Disclosed is a tolerogenic peptide capable of binding an MHC class II molecule independent of antigen processing for use in the treatment of type 1 diabetes, wherein the peptide is derived from a protein expressed by a pancreatic cell.
Owner:THE UNIV OF BIRMINGHAM
Compositions and methods for use in immunotherapy
Provided herein are CasX:gNA systems, and compositions and methods relating thereto, the systems comprising CasX proteins, guide nucleic acids (gNAs), and optionally donor template nucleic acids useful for the modification cell genes encoding proteins involved in antigen processing, antigen presentation, antigen recognition, and / or antigen response, as well as methods of producing and using populations of cells comprising these modified genes. In some embodiments, the modified cells further express chimeric antigen receptors (CAR) or engineered T cell receptors (TCR). Such systems are useful for preparing cells for immunotherapy.
Owner:SCRIBE THERAPEUTICS INC
Use of carnosic acid as an erap1 inhibitor for the preparation of a medicament for the treatment of ankylosing spondylitis
The application relates to the field of biotechnology, and particularly relates to the application of carnosic acid as an ERAP1 inhibitor in the preparation of a drug for treating ankylosing spondylitis of an autoimmune disease. The application first discovers that a monomer compound carnosic acid from a natural product source can be used as an ERAP1 direct targeting inhibitor in the preparation of a drug for regulating an endogenous antigen processing and presentation pathway and ankylosing spondylitis of a related autoimmune disease. The carnosic acid can be specifically combined in an ERAP1 active site through direct high-activity targeting, and the carnosic acid inhibits the activity of the ERAP1, is the highest in activity in the world, and has high selectivity in targeting the ERAP1 active site. The carnosic acid reverses the ankylosing spondylitis molecular pathological phenotypes caused by abnormal ERAP1 activity, including endoplasmic reticulum stress, reducing an extra amount of HLA-B27 molecules displayed on a cell surface, reducing the proportion of the HLA-B27 molecules incorrectly assembled on the cell surface, and maintaining normal antigen presentation functions.
Owner:SHENYANG PHARMA UNIV
Reagents and methods for treating cancer and autoimmune disease
PendingUS20260146087A1Immunoglobulin superfamilyAntibody mimetics/scaffoldsImmunologic disordersAutoimmune condition
Disclosed herein are methods for treating cancer by administering to a subject having cancer antibodies against one or more of CD300c, BTN5 (Erythroid membrane-associated protein), TAPBPL (antigen processing (TAP) binding protein like protein), Skint8 (selection and upkeep of intraepithelial T cells 8 protein), and CD300f. Also disclosed herein are methods for treating autoimmune diseases by administering to a subject having an autoimmune disease an IgV domain, or a nucleic acid encoding an IgV domain, from one or more of CD300c, BTN5, TAPBPL, Skint8, and CD300f. Also disclosed herein are antibodies against CD300c and TAPBPL, and fusion proteins that can be used in the methods for treating autoimmune disease.
Owner:UNIV OF CONNECTICUT
Active small molecule with biological orthogonal group and application thereof
PendingCN121974910APrecise and specific immune killingHighly efficient specific immune killingOrganic chemistryAntineoplastic agentsTumor targetAntiendomysial antibodies
The invention discloses an active small molecule with a biological orthogonal group and application of the active small molecule, and belongs to the technical field of biological medicine. The active small molecule is a small molecule hapten aiming at KRAS G12C mutant protein and is formed by sequentially covalently connecting a tumor targeting molecule (AMG510), a PEG Linker and a biological orthogonal group (DBCO), and the PEG chain length is 4, 10 or 16; the small-molecule hapten can be specifically combined with KRAS G12C protein inside and outside cells, after antigen processing, the small-molecule hapten is presented to the surfaces of tumor cells by MHC-I molecules to form an artificial new antigen, the artificial new antigen and an Anti-human-CD3-N3 antibody carrying an azide group are subjected to a biological orthogonal reaction, T cells are recruited and activated in situ, and accurate and efficient killing of the KRAS G12C mutant tumor cells is achieved.
Owner:CHONGQING MEDICAL UNIVERSITY
Neoantigen analysis
Cancer immunology provides a desirable new approach for cancer treatment, but verifies that the potential neoantigens to be directed against targets are cost-effective and expensive. Analysis of MHC binding affinity, antigen processing, similarity to known antigens, predicted expression levels (as mRNA or proteins), self-similarity, and mutant allele frequency provides screening methods for identifying and prioritizing candidate neoantigens using sequencing data. The methods of the invention save time and money by identifying preferential candidate neoantigens for further experimental verification.
Owner:PERSONAL GENOME DIAGNOSTICS INC
Ligand-dependent corepressor, (LCOR), mutants and fragments thereof, and uses for cancer therapy
PCT designated stageWO2026057875A1Peptide/protein ingredientsReceptors for hormonesAntigen processingLCOR
The present invention provides a novel and improved cancer therapy based on an isolated or synthesized polynucleotide sequence coding for a mutant of a Ligand-dependent corepressor (LCOR), or a fragment thereof, capable of inducing expression of the antigen processing / presentation machinery (APM) genes, wherein the mutant or fragment of a Ligand-dependent corepressor (LCOR) is characterized by comprising a functional HTH domain, and wherein said mutant or fragment of a Ligand-dependent corepressor (LCOR) is further characterized by comprising an absent or inactivated Nuclear Receptor Binding Domain.
Owner:MEDICAL RES HOSPITAL INST FOUNDATION
Gp96 tumor neoantigen prediction method and application
The application discloses a gp96 tumor neoantigen prediction method and application thereof, and relates to the technical field of tumor neoantigen prediction. The method comprises the following steps: S1, isolation and purification of gp96-tumor polypeptide complexes; S2, dissociation and purification of polypeptides; S3, mass spectrometric identification and sequence analysis of mutant peptides; S4, MHC affinity prediction; and S5, immunogenicity verification. The application takes gp96 as a natural biological concentrator, the captured polypeptides include products in a natural antigen processing path of tumor cells, and antigen peptide segments with potential immunological significance are enriched. In combination with MHC affinity prediction and immunogenicity function verification, the true positive rate of neoantigen screening is significantly improved. In a verification experiment on colon cancer samples, among 7 candidate neoantigens obtained through prediction, 4 can significantly activate autologous T cells of a patient to secrete IFN-gamma, and show a high immunogenicity verification positive rate.
Owner:SHENZHEN KANGERNUO BIOTECHNOLOGY CO LTD
Compositions and methods for degradation-enhanced immunotherapies
PCT designated stageWO2026080609A1Antibody mimetics/scaffoldsPeptide/protein ingredientsAntigen processingAntigen binding
The present disclosure relates to compositions and methods for inducing an immune response using a degradation-enhanced composition. In particular, the compositions comprise a degradation-enhanced immunogenic construct comprising: (a) an antigen, (b) a ligand that binds a degradation-enhancing target molecule, and (c) a linker connecting the antigen and the ligand, wherein the composition enhances antigen processing, presentation, and immune activation, thereby improving adaptive immune responses.
Owner:VIRGINIA COMMONWEALTH UNIV
An antigen filtration device
This invention provides an antigen filtration device, belonging to the technical field of antigen processing equipment. The antigen filtration device includes a body, a filtration unit, a lifting device, and a reciprocating device. The body includes a shell divided into an upper cavity and a lower cavity by a circular slide rail, with a turntable slidably connected within the circular slide rail. The filtration unit is located in the upper cavity and includes an upper tube, a lower tube, and an ultrafiltration membrane disposed within both tubes. The lifting device includes at least two support parts and a lifting part. The flange of the upper tube can be placed in an adapter groove, and the upper and lower tubes are fixed together by washers and bolts. This not only facilitates the disassembly of the upper and lower tubes but also enhances their sealing. Furthermore, the upper and lower tubes form an integrated structure, allowing for rapid secondary filtration after primary filtration, thereby improving filtration efficiency.
Owner:QINGDAO RAISECARE BIOTECHNOLOGY CO LTD